


FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis

Updates on PsA: Insights into the Latest Psoriatic Arthritis Treatments & Research

FDA Discussed 2021 Drug Warnings & Approvals at ACR Annual Meeting

Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis

Tips for Transitioning Patients from Pediatric to Adult Rheumatology Care

FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use

Health Canada Approves Upadacitinib to Treat Adults with PsA

Upadacitnib for RA: Researchers Compared Upadacitinib with Placebo & Adalimumab in Patients with RA & an Inadequate Response to Methotrexate

European Commission Approves Upadacitinib for Psoriatic Arthritis & Ankylosing Spondylitis
- 1
- 2
- 3
- 4
- Next Page »